Literature DB >> 22326534

Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression.

Hong Yu1, Gang Zhao, Hui Li, Xiaojian Liu, Shijun Wang.   

Abstract

The present study was designed to investigate the underlying molecular mechanism for Angiotensin II type 1 receptor blockers (ARBs) mediated cardio-protection against pressure overload-induced cardiac remodeling with a focus on Smad7. ROCK-1, Smad3 and fibronectin expressions were increased in male C57BL/6 mice underwent transverse aortic constriction (TAC) for 2weeks. Treatment with Candesartan (2mg/kg per day) could effectively downregulate Smad3 and fibronectin accompanied by upregulating of Smad7. Further data showed that Candesartan inhibited TGF-β1 signal-induced epithelial-to-mesenchymal transition (EMT) through attenuating matrix metalloproteinases (MMP-9), such effect was abolished by knocking-down Smad7. Moreover, TAC for 2weeks caused increased collagen deposition, thickness of left ventricular anterior and posterior wall at end-diastole (LVAWD and LVPWD) and LVEF% reduction, which were reversed by treatment with Candesartan, but failed after knocking-down Smad7. In addition, LV dP/dt(max) and dP/dt(min) were increased by TAC for 2weeks, and treatment with Candesartan or Nifedipine effectively depressed the high levels of dP/dt(min) induced by TAC. However, only Candesartan-mediated protective role in improving cardiac function was suppressed by tail-vein injection of Smad7 siRNA. This study uncovered a novel role for ARBs in preventing pressure overload-induced cardiac remodeling via Smad7 upregulation, which suppressed MMP-9 expression and TGF-β1 signal-mediated EMT progress. Crown Copyright Â
© 2012. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326534     DOI: 10.1016/j.gene.2012.01.081

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  7 in total

1.  Serelaxin and the AT2 Receptor Agonist CGP42112 Evoked a Similar, Nonadditive, Cardiac Antifibrotic Effect in High Salt-Fed Mice That Were Refractory to Candesartan Cilexetil.

Authors:  Yan Wang; Lei Han; Matthew Shen; Emma S Jones; Iresha Spizzo; Sarah L Walton; Kate M Denton; Tracey A Gaspari; Chrishan S Samuel; Robert E Widdop
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-23

2.  AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.

Authors:  Bryna S M Chow; Martina Kocan; Matthew Shen; Yan Wang; Lei Han; Jacqueline Y Chew; Chao Wang; Sanja Bosnyak; Katrina M Mirabito-Colafella; Giannie Barsha; Belinda Wigg; Elizabeth K M Johnstone; Mohammed A Hossain; Kevin D G Pfleger; Kate M Denton; Robert E Widdop; Roger J Summers; Ross A D Bathgate; Tim D Hewitson; Chrishan S Samuel
Journal:  J Am Soc Nephrol       Date:  2019-09-11       Impact factor: 10.121

3.  Overexpression of Smad7 suppressed ROS/MMP9-dependent collagen synthesis through regulation of heme oxygenase-1.

Authors:  Hong Yu; Junxing Huang; Shijun Wang; Gang Zhao; Xia Jiao; Li Zhu
Journal:  Mol Biol Rep       Date:  2013-05-10       Impact factor: 2.316

Review 4.  The role of Smad signaling cascades in cardiac fibrosis.

Authors:  Anis Hanna; Claudio Humeres; Nikolaos G Frangogiannis
Journal:  Cell Signal       Date:  2020-11-05       Impact factor: 4.315

5.  Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction.

Authors:  Gwo-Jyh Chang; Yung-Hsin Yeh; Wei-Jan Chen; Yu-Shien Ko; Ying-Ju Lai; Yun-Shien Lee
Journal:  J Am Heart Assoc       Date:  2022-07-19       Impact factor: 6.106

Review 6.  Venous endothelial injury in central nervous system diseases.

Authors:  Jonathan S Alexander; Leonard Prouty; Ikuo Tsunoda; Chaitanya Vijay Ganta; Alireza Minagar
Journal:  BMC Med       Date:  2013-10-11       Impact factor: 8.775

7.  Single intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling.

Authors:  Neus Bellera; Ignasi Barba; Antonio Rodriguez-Sinovas; Eulalia Ferret; Miguel Angel Asín; M Teresa Gonzalez-Alujas; Jordi Pérez-Rodon; Marielle Esteves; Carla Fonseca; Nuria Toran; Bruno Garcia Del Blanco; Amadeo Pérez; David Garcia-Dorado
Journal:  J Am Heart Assoc       Date:  2014-09-19       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.